Heart transplantation

On this page

Indications & Contraindications - The Gatekeepers' List

  • Indications: Generally, end-stage heart disease with <1 year life expectancy.

    • Refractory cardiogenic shock, NYHA Class III-IV HF
    • Intractable angina or malignant arrhythmias
    • LVEF <20%
    • Peak VO₂ <14 mL/kg/min
  • Contraindications:

    • Absolute:
      • Active malignancy
      • Severe, irreversible pulmonary hypertension (PVR >5 Wood units)
      • Irreversible end-organ damage (e.g., liver, kidney)
      • Active systemic infection
    • Relative:
      • Age >70
      • Poorly controlled diabetes
      • Active substance abuse
      • Psychosocial instability

Exam Favorite: Irreversible pulmonary hypertension (high Pulmonary Vascular Resistance) is a critical absolute contraindication, as the donor right ventricle is not accustomed to high afterload and will fail.

Donor-Recipient Matching - The Perfect Match

Key matching criteria aim to minimize rejection and maximize graft survival.

  • ABO Blood Group: Must be identical or compatible.
  • Panel Reactive Antibody (PRA): Screens for pre-formed HLA antibodies. A high PRA indicates sensitization, making matching difficult.
  • Size Match: Donor weight should be within 30% of the recipient's weight.

⭐ Cytomegalovirus (CMV) status is critical. A CMV-negative recipient should ideally receive a CMV-negative heart to prevent primary infection, a major cause of post-transplant morbidity.

Surgical Procedure - The New Engine Swap

  • Standard Approach: Median sternotomy & initiation of cardiopulmonary bypass (CPB).
  • Orthotopic Transplant (Biatrial Technique): Recipient's heart is explanted, leaving posterior walls of the atria with vena cavae and pulmonary veins intact.
  • Anastomosis Sequence: Left atrium → Right atrium → Pulmonary artery → Aorta.

image

EKG Finding: The recipient's native sinoatrial (SA) node remnant can remain functional, leading to two P-waves (one from donor, one from recipient) on post-op EKG.

Immunosuppression & Rejection - Taming the Defenses

  • Induction Therapy: Basiliximab (IL-2R antagonist) at time of transplant.

  • Maintenance (Triple Drug Regimen):

    • Calcineurin Inhibitor (CNI): Tacrolimus (preferred) or Cyclosporine.
    • Antiproliferative: Mycophenolate Mofetil (MMF) or Azathioprine.
    • Corticosteroids: Prednisone, with gradual taper.
  • Types of Rejection:

    • Hyperacute: Minutes; pre-formed antibodies; causes thrombosis.
    • Acute Cellular: 1-12 weeks; T-cell mediated; diagnosed via biopsy.
    • Antibody-Mediated (AMR): Can occur anytime; donor-specific antibodies (DSAs).
    • Chronic: >1 year; leads to Cardiac Allograft Vasculopathy (CAV).

⭐ Endomyocardial biopsy is the gold standard for monitoring and diagnosing acute cardiac allograft rejection, revealing lymphocytic infiltrate and myocyte damage.

Heart transplant rejection: cellular and antibody-mediated

Complications & Prognosis - The Long Road Ahead

  • Infection: Highest risk in first year. Prophylaxis is key.
    • Timeline: Bacterial (early) → Opportunistic (CMV, Pneumocystis) → Fungal (late).
  • Malignancy: Due to ↓ immune surveillance.
    • Most common: Skin cancers (Squamous Cell > Basal Cell).
    • Post-transplant Lymphoproliferative Disorder (PTLD), often EBV-driven.
  • Graft Failure:
    • Acute/chronic rejection.
    • Cardiac Allograft Vasculopathy (CAV).

Cardiac Allograft Vasculopathy (CAV) is a diffuse, accelerated form of coronary artery disease and the leading cause of graft failure >1 year post-transplant.

Cardiac Allograft Vasculopathy Histopathology

  • Prognosis: Median survival is ~12-13 years. 1-year survival >85%.

High‑Yield Points - ⚡ Biggest Takeaways

  • Orthotopic transplantation is the standard for end-stage heart failure refractory to medical therapy.
  • Key contraindications include irreversible pulmonary hypertension, active malignancy, and systemic infection.
  • Endomyocardial biopsy is the gold standard for diagnosing acute cellular rejection.
  • Cardiac Allograft Vasculopathy (CAV) is a major long-term cause of graft failure, presenting as diffuse coronary stenosis.
  • Lifelong triple-drug immunosuppression increases risk of infection (CMV) and malignancy.
  • The denervated donor heart has a higher resting heart rate and is unresponsive to atropine.

Practice Questions: Heart transplantation

Test your understanding with these related questions

A 31-year-old female receives a kidney transplant for autosomal dominant polycystic kidney disease (ADPKD). Three weeks later, the patient experiences acute, T-cell mediated rejection of the allograft and is given sirolimus. Which of the following are side effects of this medication?

1 of 5

Flashcards: Heart transplantation

1/4

What type of graft is from self? _____

TAP TO REVEAL ANSWER

What type of graft is from self? _____

Autograft

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial